Treats metastatic colorectal cancer. ANDA 211003, held by Meitheal. Levoleucovorin Calcium.
As of Nov 16, 2026, ANDA 211003 (Levoleucovorin Calcium), held by Meitheal, was first approved by FDA on Aug 22, 2019, with 2 approved supplements and 0 published complete response letters.
Levoleucovorin for Injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Levoleucovorin for Injection is a folate analog indicated for: Rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. Diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 22, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Levoleucovorin CalciumEQ 50MG BASE/VIAL · powder;intravenous | Levoleucovorin Calcium | Discontinued |
| Sep 22, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 22, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 22, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters